Rifkin, Robert M.
Bell, Jill A.
DasMahapatra, Pronabesh
Hoole, Michael
Lowe, Maria
Curran, Chris
Campbell, Scott
Hou, Peijie
Romanus, Dorothy
Funding for this research was provided by:
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
First Online: 11 October 2019
Compliance with Ethical Standards
:
: RR is an employee of the Rocky Mountain Cancer Centers, received funding from the study sponsor, and has received consulting honoraria from or has membership on the following entities’ board of directors or advisory committees: Amgen, Celgene, Takeda, Janssen. JB, SC, and DR are employees of Millennium Pharmaceuticals, Inc. PH was an employee of Millennium Pharmaceuticals, Inc. at the time of the study. PD was an employee of PatientsLikeMe at the time of the study and received funding from the study sponsor. MH, ML, and CC are employees of PatientsLikeMe and have received funding from the study sponsor.
: The study received ethical approval from the New England Institutional Review Board. Patients provided informed consent electronically prior to completing the survey. Respondents were not remunerated for their participation.
: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.